FDA Greenlights Treatment for Acute Pancreatitis Risk in Severe Hypertriglyceridemia
IONS has more than doubled off its 52-week low of $37.32.
Summary
The FDA has approved a new treatment to reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia. This is a significant regulatory milestone for Ionis, allowing the company to commercialize the drug and open a new revenue stream. This approval follows a period of positive news for Ionis, including strong Q1 results and positive clinical data for other pipeline assets, such as the long-term data for olezarsen announced on June 12th.
At the time of this announcement, IONS was trading at $76.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $37.32 to $86.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.